Label:Information for the User
Softacort 3.35 mg/ml eye drops in single-dose solution
Sodium phosphate of hydrocortisone
Read this label carefully before starting to use this medication,because it contains important information for you.
1.What isSoftacortand what is it used for
2.What you need to knowbeforestarting touseSoftacort
3.How to useSoftacort
4.Possible adverse effects
6.Contents of the package and additional information
This medication is a single-dose solution eye drop that contains a substance called hydrocortisone. This substance is a corticosteroid that inhibits the symptoms of inflammation.
It is used to treat mild allergic or inflammatory conditions of the superficial part of your eye or eyes (conjunctiva).
The eye should not be infected (see Do not use Softacort).
Do not use Softacort
Warnings and precautions
Children
No safety and efficacy data are available in children.
Prolonged treatment with corticosteroids can cause adrenal suppression.
In children, increased intraocular pressure occurs more frequently, with greater severity, and more rapidly than in adults.
Use of Softacort with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication, including over-the-counter medications.
Some medications may increase the effects of Softacort, and your doctor may wish to monitor you closely if you are using these medications (including some HIV medications: ritonavir, cobicistat).
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
The safety of this medication during breastfeeding is unknown. Your doctor will decide if you can use or not use this medication during breastfeeding.
Driving and operating machinery
You may experience blurred vision immediately after applying Softacort. Do not drive or operate machinery until this effect has disappeared.
Softacort contains phosphates
This medication contains 0.227 mg of phosphates in each drop.
Follow exactly the administration instructions of this medication as indicated by your doctor or pharmacist.This medication should be used exactly as directed.In case of doubt, consult your doctor or pharmacist again.
The recommended dose is 2 drops in the (the) affected eye(s), 2 to 4 times a day, as prescribed by a doctor.A gradual reduction in dose is recommended to avoid a relapse.The treatment duration may vary from a few days to a maximum of 14 days.
The same dose is used for both adults and elderly patients.
Use in children
The efficacy and safety in children have not been established.
Instructions for use
This medication is intended to be administered in the eye.
To use the eye drops, please follow these instructions:
8.Press the affected eye with your finger, near the nose. Apply pressure for 1 minute, keeping your eye closed.
If you use any other eye drops, wait at least 5 minutes between each application.
Using more Softacort than you should
Rinse the eye with sterile water if too much product has been administered to the eye and prolonged irritation occurs.
Contact your doctor or pharmacist immediately.
Missing a dose of Softacort
You should not apply an additional drop to the eye to compensate for the missed dose.
Stopping treatment with Softacort
Do not stop treatment abruptly.Always consult your doctor if you are considering discontinuing treatment.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Unknown frequency:cannot be estimated from the available data
The following side effects have been reported with medications in the same group (corticosteroids) when used to treat eye conditions.
Unknown frequency:cannot be estimated from the available data
If you suffer from severe damage to the transparent layer at the front of the eye (cornea), treatment with phosphates, in rare cases, may cause cloudy patches in the cornea due to calcium.
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https//: notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box, on the blister pack, and on the single-use container after CAD or EXP. The expiration date is the last day of the month indicated.
Store below25°C.
After the first opening of the blister pack:use the single-use container within a month.
Keep the single-use containers inside the blister pack to protect them from light.
Write the date of the first opening of the blister pack.
After the first opening of the single-use container:use immediately and discard the single-use container after use.
Sterility cannot be maintained after opening a single-use container, so you must open a new container before each use.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Composition ofSoftacort
1 ml of eye drop solution contains 3.35 mg of hydrocortisone sodium phosphate.
Appearance of the product and contents of the package
This medication is presented as an eye drop solution in single-dose containers.
The solution is practically transparent, colorless to slightly yellow, practically free of particles, presented in the interior of a package with 10 units, each single-dose container contains 0.4 ml of eye drop solution.
The boxes contain 10 (1 x 10), 20 (2 x 10), 30 (3 x 10), or 60 (6 x 10) single-dose containers.
Only some package sizes may be commercially available.
Holder of the marketing authorization and responsible manufacturer
Holder of the marketing authorization
Laboratoires THEA
12 RUE LOUIS BLERIOT
63017 CLERMONT-FERRAND CEDEX 2
FRANCE
Manufacturer
Laboratoires UNITHER
1 rue de l’Arquerie
50200 Coutances
FRANCE
or
Laboratoires THEA
12, rue Louis Blériot
63017 CLERMONT-FERRAND Cedex 2
FRANCE
Local representative
Laboratorios THEA, S.A.
C/ Enric Granados nº 86-88, 2nd floor
08008 – BARCELONA
This medication is authorized in the member states of the European Economic Area with the following names:
Germany, Austria, Bulgaria, Cyprus, Croatia, Denmark, Slovenia, Spain, Finland, France, Greece, Iceland, Norway, Poland, Portugal, Czech Republic, Slovak Republic, United Kingdom, Romania, SwedenSoftacort
Belgium, Netherlands, LuxembourgSoftacor
IrelandZoftazot
ItalySofacor
Last review date of this leaflet: October 2023
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.